Furthermore, administration of AGX‐51 reduced the availability of VEGF, the leading angiogenic protein essential for neovascularisation and vascular permeability [59, 60], documented to promote VM by cancer cells [61] and a known regulatory target of ID1 [62]. The gene discussed is ID1; the disease is cancer.